Detection and Treatment of Retinoblastoma
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".
Deadline for manuscript submissions: closed (31 October 2021) | Viewed by 20426
Special Issue Editors
Interests: adult and pediatric ocular oncology
Special Issue Information
Dear Colleagues,
Rb, the most common primary intraocular malignancy of childhood is an uncommon paediatric cancer, with a constant incidence worldwide of 1:15,000–1:20,000 live births. However, its position in oncology is unique as it has served as a benchmark in terms of tumour diagnosis, classification and management. It was the first human cancer treated in the 1920s with an early attempt at brachytherapy and in the 1950s with a linear accelerator. It is initiated by a mutation in the RB1 gene, which was the first described tumour suppressor gene, in the 1970s and 1980s. It has become the first cancer for which a hereditary component was added to its AJCC TNM classification schema (i.e., TNMH).
Rb is also one of the most prominent successes among all paediatric oncology. From nearly 100% mortality a century ago, there is now over 98% survival in developed countries. It is an eye tumour that was treated just over half a century ago only by means of enucleation, but which today can be treated conservatively with retention of functional vision. Many factors have contributed to this: better understanding of the genetic basis of the disease, establishment of specialist centres, primary care infrastructure and public awareness campaigns, and in no small measure, to the dramatic evolution of Rb management and treatment options over the last century, the abandonment of external beam radiotherapy and the onset of chemotherapy and development of targeted chemotherapy into the ophthalmic artery or the vitreous cavity. Nonetheless, the burden of disease is greatest in developing countries, and challenges remain in improving outcomes for all children and their families dealing with this disease.
In this Special Issue of Cancers, we wish to curate an edition with cutting-edge knowledge and invite articles with new findings or pertinent reviews in retinoblastoma.
Prof. Mandeep S. Sagoo
Dr. Maddy Ashwin Reddy
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- retinoblastoma
- chemotherapy
- intra-arterial chemotherapy
- intravitreal chemotherapy
- brachytherapy
- genetics
- surgery
- enucleation
